このページの翻訳は実験的なもので、現在開発中です。お待ちしております！

AstraZeneca 将来の成長

Future 基準チェック /46

AstraZeneca利益と収益がそれぞれ年間14.8%と6.1%増加すると予測されています。EPS は年間増加すると予想されています。自己資本利益率は 3 年後に31.3% 15.3%なると予測されています。

主要情報

14.7%

収益成長率

15.3%

EPS成長率

Pharmaceuticals 収益成長	14.2%
収益成長率	6.1%
将来の株主資本利益率	31.3%
アナリストカバレッジ	Good
最終更新日	13 Jun 2024

今後の成長に関する最新情報

Earnings Update: AstraZeneca PLC Beat Earnings And Now Analysts Have New Forecasts For This Year

Apr 27

Recent updates

These 4 Measures Indicate That AstraZeneca (LON:AZN) Is Using Debt Reasonably Well

Jun 05

Earnings Update: AstraZeneca PLC Beat Earnings And Now Analysts Have New Forecasts For This Year

Apr 27

AstraZeneca PLC's (LON:AZN) P/E Is On The Mark

Mar 30

Is There An Opportunity With AstraZeneca PLC's (LON:AZN) 30% Undervaluation?

Mar 15

業績と収益の成長予測

LSE:AZN - アナリストの将来予測と過去の財務データ ( )USD Millions
日付	収益	収益	フリー・キャッシュフロー	営業活動によるキャッシュ	平均アナリスト数
12/31/2026	58,835	11,674	13,758	16,115	21
12/31/2025	55,575	10,450	11,806	14,473	26
12/31/2024	51,685	8,786	8,689	11,666	26
3/31/2024	47,611	6,331	5,887	9,698	N/A
12/31/2023	45,811	5,955	6,858	10,345	N/A
9/30/2023	44,994	5,896	7,270	10,363	N/A
6/30/2023	44,485	6,163	6,854	10,179	N/A
3/31/2023	43,840	4,705	6,357	9,709	N/A
12/31/2022	44,351	3,288	7,684	9,808	N/A
9/30/2022	45,155	2,040	6,538	8,828	N/A
6/30/2022	44,038	-1,253	5,789	7,617	N/A
3/31/2022	41,487	-1,063	5,721	7,261	N/A
12/31/2021	37,417	112	4,350	5,963	N/A
9/30/2021	32,816	1,471	5,184	6,343	N/A
6/30/2021	29,528	3,771	5,421	6,446	N/A
3/31/2021	27,583	3,977	4,899	6,594	N/A
12/31/2020	26,617	3,196	3,144	4,799	N/A
9/30/2020	25,871	2,497	3,273	4,376	N/A
6/30/2020	25,699	2,148	3,057	3,657	N/A
3/31/2020	25,247	1,522	2,789	3,495	N/A
12/31/2019	24,384	1,335	2,585	2,969	N/A
9/30/2019	24,137	2,056	4,230	3,818	N/A
6/30/2019	23,071	2,188	3,543	3,184	N/A
3/31/2019	22,403	2,408	3,621	2,371	N/A
12/31/2018	22,090	2,155	3,585	2,618	N/A
9/30/2018	21,450	2,422	1,202	1,391	N/A
6/30/2018	22,342	2,677	2,854	3,165	N/A
3/31/2018	22,238	2,804	3,468	3,350	N/A
12/31/2017	22,465	3,001	N/A	3,578	N/A
9/30/2017	22,273	3,542	N/A	4,541	N/A
6/30/2017	21,740	3,870	N/A	3,109	N/A
3/31/2017	22,292	3,390	N/A	3,040	N/A
12/31/2016	23,002	3,499	N/A	4,145	N/A
9/30/2016	23,816	2,465	N/A	2,756	N/A
6/30/2016	24,062	2,221	N/A	3,690	N/A
3/31/2016	24,766	2,921	N/A	4,589	N/A
12/31/2015	24,708	2,825	N/A	3,324	N/A
9/30/2015	25,025	1,696	N/A	4,595	N/A
6/30/2015	25,689	1,180	N/A	4,800	N/A
3/31/2015	26,144	1,279	N/A	5,799	N/A
12/31/2014	26,547	1,233	N/A	7,058	N/A
9/30/2014	26,675	1,030	N/A	7,694	N/A
6/30/2014	26,316	2,022	N/A	6,862	N/A
3/31/2014	25,786	2,049	N/A	6,389	N/A
12/31/2013	25,806	2,556	N/A	7,400	N/A
9/30/2013	26,149	4,587	N/A	7,770	N/A
6/30/2013	26,581	4,852	N/A	7,961	N/A

アナリストによる今後の成長予測

収入対貯蓄率: AZNの予測収益成長率 (年間14.8% ) は貯蓄率 ( 1.8% ) を上回っています。

収益対市場: AZNの収益 ( 14.8% ) はUK市場 ( 13.2% ) よりも速いペースで成長すると予測されています。

高成長収益: AZNの収益は増加すると予測されていますが、大幅には増加しません。

収益対市場: AZNの収益 ( 6.1% ) UK市場 ( 3.7% ) よりも速いペースで成長すると予測されています。

高い収益成長: AZNの収益 ( 6.1% ) 20%よりも低い成長が予測されています。

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: AZNの自己資本利益率は、3年後には高くなると予測されています ( 31.3 %)

AstraZeneca 将来の成長

Future 基準チェック /46

主要情報

今後の成長に関する最新情報

Earnings Update: AstraZeneca PLC Beat Earnings And Now Analysts Have New Forecasts For This Year

AstraZeneca PLC Reiterates Earnings Guidance for the Year 2024

Recent updates

Daiichi Sankyo and AstraZeneca PLC Provides Positive Results from the DESTINY-Breast06 Phase 3 Trial

These 4 Measures Indicate That AstraZeneca (LON:AZN) Is Using Debt Reasonably Well

AstraZeneca's Tagrisso (Osimertinib) Announces the Addition of Pemetrexed and Platinum-Based Chemotherapy Recommended for Approval in the European Union for 1St-Line Treatment of Adult Patients

Daiichi Sankyo and AstraZeneca PLC Provides an update on TROPION-Lung01 Phase 3 Trial

AstraZeneca PLC Phase III Trial of Sipavibart Long-Acting Antibody Met Primary Endpoints in Preventing COVID-19 in Immunocompromised Patient Population

AstraZeneca PLC Announces Positive High-Level Results from an Interim Analysis of the Echo Phase III Trial

AstraZeneca PLC and Daiichi Sankyo Announces ENHERTU (Fam-Trastuzumab Deruxtecan-Nxki) Improved PFS in HER2-Low and Ultralow

Earnings Update: AstraZeneca PLC Beat Earnings And Now Analysts Have New Forecasts For This Year

AstraZeneca PLC Reiterates Earnings Guidance for the Year 2024

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

Astrazeneca plc Announces IMFINZI (Durvalumab) Plus Chemotherapy Doubled Overall Survival Rate At Three Years for Patients with Advanced Biliary Tract Cancer in Topaz-1 Phase III Trial

AstraZeneca’s FASENRA Approves for Treatment of Children Aged 6 to 11 with Severe Asthma by the US Food and Drug Administration

AstraZeneca PLC Intends to Increase the Annualized Dividend for 2024

AstraZeneca PLC's Imfinzi Shows Significantly Improved Overall Survival and Progression-Free Survival for Patients with Limited-Stage Small Cell Lung Cancer in Adriatic Phase III Trial

Datopotamab Deruxtecan Biologics License Application Accepted in the U.S. for Patients with Previously Treated Metastatic HR Positive, HER2 Negative Breast Cancer

AstraZeneca PLC's (LON:AZN) P/E Is On The Mark

AstraZeneca PLC Announces Ultomiris Approved in the US for the Treatment of Adults with Neuromyelitis Optica Spectrum Disorder

AstraZeneca PLC (LSE:AZN) entered into a definitive agreement to acquire Fusion Pharmaceuticals Inc. (NasdaqGS:FUSN) for $1.5 billion.

Is There An Opportunity With AstraZeneca PLC's (LON:AZN) 30% Undervaluation?

AstraZeneca PLC (LSE:AZN) agreed to acquire Amolyt Pharma SAS for $1.05 billion.

業績と収益の成長予測

アナリストによる今後の成長予測

一株当たり利益成長率予想

将来の株主資本利益率

成長企業の発掘